Skip to main content

Table 3 Factors associated with 30-day mortality by univariate and multivariate analysis

From: Factors related to mortality in critically ill histoplasmosis: a multicenter retrospective study in Guadeloupe and French Guyana

 

30-day survivors (n = 19)

30-day non-survivor (n = 21)

Univariate analysis

Multivariate analysis

OR (95%CI)

p

OR (95% CI)

p

Female, n (%)

8 (44)

6 (29)

    

Age, years

57 (46–61)

55 (41–62)

1 (1.0–1.0)

0.882

  

SOFA score

8 (6–11)

14 (10–16)

1.3 (1.1–1.6)

0.001

1.5 (1.1–2.1)

0.01

Geographic origin, French Guyana, n (%)

5 (33)

8 (40)

1.3 (0.3–5.8)

0.707

  

Time between

 Symptom onset and ICU admission, days

15 (10–28.5)

28 (20–34)

1.0 (1.0–1.1)

0.078

  

 Symptom onset and treatment, days

16 (11–32)

29 (21–40)

1.0 (1.0–1.1)

0.078

1.1 (1.0–1.1)

0.02

 ICU admission and treatment, days

1 (0–2)

2 (0–4)

1.1 (0.9 –1.3)

0.139

  

Underlying immunodeficiency

 HIV-infected, n (%)

9 (47)

14 (67)

0.151

  

 Other immunodeficiency, n (%)

8 (42)

3 (14)

0.26 (0.0–1.2)

   

 No identified immunodeficiency, n (%)

2 (11)

4 (19)

1.2 (0.2–11.7)

   

Clinical features

 Temperature, °C

39 (38–40)

39 (38–40)

0.9 (0.6–1.5)

0.891

  

 Neurological symptoms, n (%)

5 (26)

11 (52)

3.0 (0.8–12.4)

0.175

  

 Respiratory symptoms, n (%)

19 (100)

19 (90)

 

0.488

  

 Gastrointestinal symptoms, n (%)

11 (58)

12 (57)

1.0 (0.3–3.5)

1.0

  

Biological data

 Lactate, mmol/L

2 (2 –3)

3 (2 –5)

1.6 (1.0–2.4)

0.035

  

 Ferritinemia, UI/L

10000 (3000–35000)

40000 (40000–47500)

1.0 (1.0–1.0)

0.012

  

 Platelets, G/L

92 (54–205)

26 (12–96)

1.0 (1.0–1.0)

0.096

  

 Creatinine, µmol /L

102 (70–344)

206 (110–476)

1.0 (1.0–1.0)

0.110

  

 Triglycerides, mmol/L

2.5 (2.3–4.0)

3.1 (2.9–3.3)

1.1 (0.5–2.8)

0.569

  

 LDH, UI/L

500 (400–935)

989 (468–1224)

1.0 (1.0–1.0)

0.317

  

 CRP, mg/L

150 (87–222)

146 (95–255)

1.0 (1.0–1.0)

0.910

  

Severe organ involvement

 Acute respiratory failure, n (%)

16 (84)

18 (86)

1.1 (0.2–7.4)

1.0

  

 Shock, n (%)

10 (53)

21 (100)

 

 < 0.001

  

Coma, n (%)

3 (16)

9 (43)

3.8 (0.9–21.1)

0.128

  

 Hemophagocytic lymphohistiocytosis, n (%)

4 (21)

15 (71)

8.6 (2.1–42.6)

0.004

6.4 (1.1–47.5)

0.05

 Disseminated histoplasmosis, n (%)

15 (79)

17 (81)

1.1 (0.2–5.3)

0.878

  

Advanced life support therapy

 Renal replacement therapy, n (%)

6 (32)

16 (76)

6.5 (1.7–29.2)

0.006

  

 Mechanical ventilation, n (%)

10 (53)

21 (100)

 

 < 0.001

  
  1. Results are median (25th–75th quartiles) for continuous variables, number n (percentage) for categorical variables, and odds ratio (OR) and 95% confidence interval (CI)
  2. HIV human immunodeficiency virus; SOFA Sequential Organ Failure Assessment; LDH lactate dehydrogenase; CRP C-reactive protein; ICU intensive care unit